Paul Hartmann AG (STU:PHH2) Beneish M-Score: -2.68 (As of Jun. 28, 2026)


STU:PHH2 Paul Hartmann AG STU:PHH2
61 GF Score
Price €205.00
GF Value €229.60
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Paul Hartmann AG Beneish M-Score?

Paul Hartmann AG STU:PHH2 +0.49% 61 Beneish M-Score is -2.68 as of Jun. 28, 2026. GuruFocus rates STU:PHH2 with a GF Score™ of 61/100 and a GF Value™ of €229.60 (Fairly Valued). The stock has 4 warning signs investors should review. Among 766 Medical Devices & Instruments companies, Paul Hartmann AG ranks better than 58.88% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.68 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Paul Hartmann AG's Beneish M-Score or its related term are showing as below:

STU:PHH2' s Beneish M-Score Range Over the Past 10 Years
Min: -3.08   Med: -2.69   Max: -2.45
Current: -2.68

During the past 13 years, the highest Beneish M-Score of Paul Hartmann AG was -2.45. The lowest was -3.08. And the median was -2.69.


Paul Hartmann AG Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Paul Hartmann AG's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paul Hartmann AG Beneish M-Score Chart

Paul Hartmann AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.45 -2.48 -2.88 -2.69 -2.68

Paul Hartmann AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.88 0.00 -2.69 0.00 -2.68

STU:PHH2 vs ISRG, BDX, MDLN: Beneish M-Score Comparison

For the Medical Instruments & Supplies subindustry, Paul Hartmann AG's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Paul Hartmann AG Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Paul Hartmann AG's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Paul Hartmann AG's Beneish M-Score falls into.


STU:PHH2
61GF Score
Paul Hartmann AG STU:PHH2
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Paul Hartmann AG Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Paul Hartmann AG for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0258+0.528 * 0.9906+0.404 * 0.9397+0.892 * 1.0173+0.115 * 1.0322
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.01+4.679 * -0.043329-0.327 * 1.0167
=-2.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was €427 Mil.
Revenue was €2,450 Mil.
Gross Profit was €1,479 Mil.
Total Current Assets was €1,114 Mil.
Total Assets was €2,161 Mil.
Property, Plant and Equipment(Net PPE) was €747 Mil.
Depreciation, Depletion and Amortization(DDA) was €109 Mil.
Selling, General, & Admin. Expense(SGA) was €280 Mil.
Total Current Liabilities was €501 Mil.
Long-Term Debt & Capital Lease Obligation was €263 Mil.
Net Income was €61 Mil.
Gross Profit was €0 Mil.
Cash Flow from Operations was €155 Mil.
Total Receivables was €409 Mil.
Revenue was €2,408 Mil.
Gross Profit was €1,440 Mil.
Total Current Assets was €1,095 Mil.
Total Assets was €2,098 Mil.
Property, Plant and Equipment(Net PPE) was €692 Mil.
Depreciation, Depletion and Amortization(DDA) was €105 Mil.
Selling, General, & Admin. Expense(SGA) was €273 Mil.
Total Current Liabilities was €466 Mil.
Long-Term Debt & Capital Lease Obligation was €264 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(426.986 / 2449.619) / (409.142 / 2407.917)
=0.174307 / 0.169915
=1.0258

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1440.167 / 2407.917) / (1478.961 / 2449.619)
=0.598097 / 0.603751
=0.9906

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1113.888 + 746.539) / 2161.147) / (1 - (1094.778 + 692.441) / 2097.867)
=0.139148 / 0.148078
=0.9397

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2449.619 / 2407.917
=1.0173

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(104.758 / (104.758 + 692.441)) / (108.906 / (108.906 + 746.539))
=0.131408 / 0.127309
=1.0322

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(280.105 / 2449.619) / (272.617 / 2407.917)
=0.114346 / 0.113217
=1.01

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((262.582 + 501.357) / 2161.147) / ((263.815 + 465.595) / 2097.867)
=0.353488 / 0.347691
=1.0167

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(61.213 - 0 - 154.853) / 2161.147
=-0.043329

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Paul Hartmann AG has a M-score of -2.68 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.68 mean?
Paul Hartmann AG (STU:PHH2) has a Beneish M-Score of -2.68 as of Jun. 28, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Paul Hartmann AG and its competitors. According to the industry distribution chart, Paul Hartmann AG ranks #315 out of 766 companies in the Medical Devices & Instruments industry, placing it in the top 41.1%.
Is Paul Hartmann AG's Beneish M-Score too high?
Paul Hartmann AG's current Beneish M-Score is -2.68. Based on the distribution chart, Paul Hartmann AG ranks #315 out of 766 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Paul Hartmann AG has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Paul Hartmann AG's Beneish M-Score compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Paul Hartmann AG ranks #315 out of 766 companies for Beneish M-Score. This puts Paul Hartmann AG in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Paul Hartmann AG and its competitors. Paul Hartmann AG's current Beneish M-Score is -2.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paul Hartmann AG stock overvalued right now?
Based on GuruFocus' analysis, Paul Hartmann AG (STU:PHH2) is currently considered Fairly Valued. The stock's GF Value™ is €229.60, compared to a current price of €205.00 — trading 10.7% below its estimated fair value. The current Beneish M-Score is -2.68. Paul Hartmann AG's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Paul Hartmann AG (STU:PHH2), the current Beneish M-Score is -2.68 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Paul Hartmann AG (STU:PHH2) Overvalued in 2026?

Based on GuruFocus' analysis, Paul Hartmann AG stock appears to be undervalued. The current stock price of €205.00 is trading 10.7% below its estimated GF Value™ of €229.60. GuruFocus considers Paul Hartmann AG to be Fairly Valued.

Key valuation signals for STU:PHH2:

  • Beneish M-Score: -2.68
  • GF Value™: €229.60 vs. price of €205.00 (10.7% below fair value)
  • GF Score™: 61/100 with 4 warning signs

No single metric tells the full story. See the STU:PHH2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Paul Hartmann AG Business Description

Other Exchanges PHH2:Germany
Address Paul-Hartmann-Strasse 12, Heidenheim, DEU, 89522
Paul Hartmann AG engages in the production of medical and hygiene products. It operates through Wound Management, Incontinence Management and Infection Management and other segments. The Wound segment comprises wound dressing and treatment, compression therapy, first aid, immobilization, and diagnostics. The Incontinence segment provides incontinence hygiene, patient care, and medical skin care. The Infection segment consists of custom procedure trays, surgical draping systems, disposable surgical instruments, and disinfectants. The Other activities include activities in cotton-wool products, medical consumer goods and pharmaceutical products and others. All the activities are functioned through the region of US and derive revenue through the sale of medical and hygiene products.
61GF Score

Get the complete analysis for STU:PHH2

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€205.00
Price
€229.60
GF Value